Advertisement
Review Article|Articles in Press, 103683

Therapeutic apheresis in ANCA Associated Vasculitis: Current status of Pexivas

Published:February 24, 2023DOI:https://doi.org/10.1016/j.transci.2023.103683
Therapeutic apheresis in ANCA Associated Vasculitis: Current status of Pexivas
Previous ArticleHematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!
Next ArticleThe role of plasmapheresis in the pulmonary-renal syndrome
      Pexivas is a Randomized Control Trial launched in June 2010 – recruitment stopped in September 2016, where 704 patients with ANCA Associated Vasculitis (AAV) presenting with eGFR lower than 50 ml/min were randomized to additional PLEX (PLEX) and two steroid protocols and followed on average 2.9 years. The results were published in 2020 [
      • Walsh M.
      • Merkel P.A.
      • Peh C.A.
      • Szpirt W.M.
      • et al.
      Plasma exchange and glucocorticoids in Severe ANCA Associated Vasculitis.
      N Engl J Med. 2020; 382: 622-631
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Walsh M.
        • Merkel P.A.
        • Peh C.A.
        • Szpirt W.M.
        • et al.
        Plasma exchange and glucocorticoids in Severe ANCA Associated Vasculitis.
        N Engl J Med. 2020; 382: 622-631
        View in Article
        • Walsh M.
        • Collister D.
        • Zeng L.
        • Merkel P.
        • Pusey C.D.
        • Guyatt G.
        • Peh C.A.
        • Szpirt W.
        • Ito-Hara T.
        • Jayne D.R.W.
        The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.
        BMJ. 2022; : 376https://doi.org/10.1136/bmj-2021-064604
        View in Article
        • Kaplan A.A.
        • Szpirt W.M.
        Should we still use therapeutic PLEX for rapidly progressive glomerulonephritis in ANCA Associated Vasculitis?.
        Kidney Dial. 2022; 2 (40): 399-406
        View in Article

      4. Fussner L..Proceedings of 2022 International Vasculitis and ANCA Workshop, 3–6 April 2022.

        View in Article
        • Gulati K.
        • Edwars H.
        • Prendecki M.
        • et al.
        Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
        Kidney Int. 2021; 100: 1316-1324
        View in Article
        • Walters G.D.
        • Narelle S.W.
        • Cooper T.E.
        • Craig J.
        Interventions for renal vasculitis in adults.
        Cochrane Database Syst Rev. 2020; 1CD003232https://doi.org/10.1002/14651858.CD003232.pub4
        View in Article
        • Yamada Y.
        • Harada M.
        • Hara Y.
        • Iwabuchi R.
        • et al.
        Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis.
        Arthritis Res Ther. 2021; 23: 28https://doi.org/10.1186/s13075-021-02415-z
        View in Article

      8. Bellos I., Boletis I., Lionaki S., A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis.Clin Rheumatol. 2021;40:1447–56.

        View in Article
        • Balogun R.A.
        • Sanchez A.P.
        • Klingel R.
        • Witt V.
        Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA-associated vasculitis.
        J Clin Apher. 2020; 35 (10.1002/jca.21820. Epub 2020 Aug 7): 493-499
        View in Article
        • Aqeel F.
        • Xu L.
        • Tomar O.
        • Duchen J.
        • Li T.
        • Geetha D.
        Practice patterns of induction therapy in severe anti-neutrophil cytoplasmic Autoantibody-Associated Vasculitis.
        Kidney Int Rep. 2022; 7: 2704-2708https://doi.org/10.1016/j.ekir.2022.08.029
        View in Article

      Article info

      Publication history

      Published online: February 24, 2023

      Publication stage

      In Press Journal Pre-Proof

      Identification

      DOI: https://doi.org/10.1016/j.transci.2023.103683

      Copyright

      © 2023 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX